Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy.

Date publication

janvier 2024

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Peisen F, Gerken A, Dahm I, Nikolaou K, Eigentler T, Amaral T, Moltz JH, Othman AE, Gatidis S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38180971

Résumé

Checkpoint inhibitors have drastically improved the therapy of patients with advanced melanoma. 18F-FDG-PET/CT parameters might act as biomarkers for response and survival and thus can identify patients that do not benefit from immunotherapy. However, little literature exists on the association of baseline 18F-FDG-PET/CT parameters with progression free survival (PFS), best overall response (BOR), and overall survival (OS).

Mots clés

Humans, Melanoma, diagnostic imaging, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Progression-Free Survival, Retrospective Studies, Neoplasms, Second Primary, Immunotherapy, Biomarkers, Glucose

Référence

PLoS One. 2024 01 5;19(1):e0296253